ADHD Therapeutics Market Size, Growth Opportunities, Revenue Share Analysis, and Forecast To 2027
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with a group of behavioral symptoms that include hyperactivity, inattentiveness and impulsiveness. The symptoms of ADHD begin in childhood and can continue through adolescence and adulthood. As per the report published by Market Research Future (MRFR), the global ADHD therapeutics market is registered to grow steadily till the end of 2024.
Market
Drivers and Restraints:
The
symptoms of ADHD such as lack of attention, hyperactivity and impulsivity
hamper proper functioning and development of an individual. Increasing
awareness regarding neurodevelopmental disorders and easy availability of diagnostic
guidelines over the internet is projected to boost the growth of the global
ADHD therapeutics market.
Request
Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1573
Changing
lifestyles and value systems along with the factors like genetic inheritance
and premature birth are resulting to the rise in prevalence of ADHD among
children in the age group of 4-17 years, which in turn is propelling the growth
of the global ADHD therapeutics market. Increasing availability of online
platforms for therapists that assure anonymity of the patient is inclining more
individuals towards undergoing therapeutic treatment for ADHD, which in turn is
fueling the expansion of the global ADHD therapeutics market
However,
underdiagnosis of ADHD due to the existence of comorbid conditions in children,
lack of awareness and low availability of non-stimulant drugs to treat ADHD in
various regions are likely to hamper the expansion of the global ADHD
therapeutics market during the forecast period.
Market
Segmentation:
The global
ADHD therapeutics market has been segmented on the basis of drug type and
distribution channel. Based on drug type, the ADHD therapeutics market is
segmented into stimulants and non-stimulants. The stimulants segment is
sub-segmented into amphetamine, methylphenidate, dextroamphetamine,
lisdexamfetamine and others. The non-stimulants segment is sub-segmented into
atomoxetine, bupropion, guanfacine and clonidine
Based on
distribution channel, the ADHD therapeutics market is segmented into hospitals,
clinics, pharmacies, research laboratories and others.
Regional
Analysis:
Geographically,
the global ADHD therapeutics market is segmented into four major regions such
as North America, Europe, Asia Pacific and the Middle East and Africa. The ADHD
therapeutics market in the North America region accounts for the dominant share
in the global ADHD therapeutics market owing to the increasing prevalence of
ADHD in the children and high healthcare expenditure by the population in this
region. The ADHD therapeutics market in the Europe region is projecting
significant growth owing to the increased research and development for the
introduction of more effective drugs in this region. The Asia Pacific region is
anticipated to grow at a notable pace in the coming years due to increased
awareness regarding ADHD and its available treatments. Whereas, the Middle East
and Africa region is projecting steady growth in the global ADHD market owing
to the low awareness and poor primary health care in the underdeveloped areas
of this region.
Industry
Updates:
In August
2018, Ironshore Pharmaceuticals & Development, Inc., a subsidiary of
Highland Therapeutics Inc., has received FDA approval for the New Drug
Application for Jornay PM (methylphenidate) which was formerly known as HLD200
which is used for the treatment of ADHD in patients of the age six and older
In August
2018, FDA has issued a Complete Response Letter (CRL) to Sunovion Pharmaceutical
asking for further clinical data to evaluate the efficacy of dasotraline, the
ADHD drug.
Key
Players:
The
prominent players profiled by MRFR in the report on the global ADHD
therapeutics market are Concordia International Corp., Eli Lilly and Company,
Highland Therapeutics Inc., Janssen Global Services LLC, NEOS Therapeutics
Inc., Novartis AG, Noven Pharmaceuticals Inc., Pfizer Inc., Shire, Teva
Pharmaceutical and others.
Browse
Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573
About
Market Research Future:
At Market
Research Future (MRFR), we enable our customers to unravel the complexity of
various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), & Consulting Services. MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients.
Have
a Look at Related Reports:
Healthcare
Analytics Market - https://www.globenewswire.com/en/news-release/2019/07/26/1892202/0/en/Healthcare-Analytics-Market-to-Witness-Steady-Growth-at-27-1-CAGR-During-2019-2024-Increasing-Adoption-of-Technological-Advancements-Boost-the-Growth-of-Global-Healthcare-Analytics.html
Healthcare
Mobility Solutions Market - https://www.globenewswire.com/en/news-release/2019/07/26/1892136/0/en/Healthcare-Mobility-Solutions-Market-Boost-by-Increasing-Medical-Needs-High-Demand-Latest-Advancements-Current-Trends-and-End-User-Approch-Towards-Healthcare-Services.html
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson
Street, 5Th Floor,
New York,
New York 10013
United
States of America
+1 628 258
0071
Email:
sales@marketresearchfuture.com
Comments
Post a Comment